🔗 Share this article

As the United States undertakes sweeping adjustments to its vaccine schedules, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines during the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her short position at the FDA.

Proposed Changes to Childhood Immunization Schedule

Agency leaders planned to announce major revisions to the childhood vaccination calendar earlier this month, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with much of the global community with no evidence for improved outcomes. This reveal has been postponed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

A New Direction at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for halting specific pediatric vaccine recommendations in the US to become more like Denmark, a nation with universal health coverage and a population roughly the population of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Qualifications

The appointee has little discernible experience in drug development, regulation or administrative roles, which has been typical for former heads of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “grasp laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

The drug center has an immense workload at the FDA, she stated.

“Everybody just focuses on the innovative therapies, but the generic program approves thousands of generic medications. There’s a biosimilars division, OTC medication office and so forth, and all of those have to be supervised,” she said. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant leadership element to the job, which supervises in excess of 5,000 personnel. “It’s a enormous management job, if you execute it properly,” she added.

Official Statement and Controversial Policies

When asked about inquiries about Dr. Høeg's credentials and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson stated that the “concerns rely on flawed presumptions”.

“This background is consistent with the responsibilities of her job,” the spokesperson explained, noting the months Høeg spent guiding the agency head on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a contentious rapid drug-approval program that reportedly concerned her predecessors. “By what process are these therapies being picked for this voucher program? Who is making the choices?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he said, “the FDA appears to be shifting towards more relaxed rules of pharmaceuticals, except for shots.”

Public History on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, track record, critics said. She released a analysis using unverified volunteer-provided data to estimate the incidence of heart inflammation after Covid immunization. She advised the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new government encompassed revising regulations for recently developed shots and ending “unnecessary” vaccines, she stated following the vote on a audio program. At the FDA, Dr. Høeg has according to sources suggested preventing adolescent males from getting COVID-19 vaccines.

“She’s an complete ideologue who commences with her conclusions and tailors the evidence to retrofit the data in a highly disingenuous, fraudulent way,” Howard said.

Taking Control and a “Push for Payback”

Høeg aligned with other skeptics, {like|